1. What Is the Psychedelic Market?
The Psychedelic Market covers investigational and commercially authorized psychedelic-assisted therapy programs, clinical research organizations, drug development companies, and licensed service centers deploying psilocybin, MDMA, ketamine, LSD analogs, and DMT-based therapies for mental health treatment. Psychiatric clinics, addiction treatment centers, mental health research institutions, and psychedelic therapy training organizations participate in a developing therapeutic ecosystem addressing treatment-resistant depression, PTSD, anxiety, and addiction through regulated psychedelic medicine protocols. The market reflects accelerating clinical trial investment, growing regulatory engagement, and expanding legal therapy access programs in Oregon, Colorado, and Australia for psilocybin and MDMA-assisted therapy.
2. Psychedelic Market Size & Forecast
3. Emerging Technologies
- Novel psychedelic drug development programs engineering shorter-duration or non-hallucinogenic compounds are advancing through Phase 1 trials, targeting therapeutic benefit without the clinical management burden of extended sessions. Growing adoption of advanced psychedelic drug development is driven by commercial opportunity in therapies that can be delivered in shorter outpatient formats compatible with standard psychiatric practice settings.
- Psychedelic therapy training and facilitator certification programs are advancing as the workforce development infrastructure supporting regulated therapy access expansion in Oregon, Colorado, and Australia. Growing adoption among therapist training programs is driven by the growing number of licensed service centers requiring certified facilitators and the commercial opportunity for trained practitioners in emerging legal markets.
- AI-powered psychedelic therapy patient preparation and integration support platforms are advancing as digital adjunct tools that extend therapeutic value between session-intensive psychedelic experiences. Growing adoption among psychedelic therapy clinics is driven by evidence that structured preparation and integration support improve durable treatment outcomes beyond the acute psychedelic session alone.
- Psychedelic drug company out-licensing and partnership programs with established pharmaceutical companies are advancing as capital-efficient commercialization pathways for clinical-stage psychedelic drug candidates. Increasing adoption is driven by clinical-stage psychedelic developer requirements for late-stage trial funding and commercial infrastructure that established pharmaceutical partners can provide.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Medical Cannabis Market.
4. Key Market Opportunity
The primary growth driver in the Psychedelic Market is the ketamine and esketamine-assisted therapy sub-market, where FDA-approved Spravato and off-label ketamine infusion services represent the commercially established and reimbursed anchor of legal psychedelic medicine. The psilocybin therapy access opportunity is a high-value growth area as Oregon and Colorado regulated service programs, Australian TGA authorization, and anticipated additional jurisdiction approvals expand legal psilocybin therapy access. MDMA-assisted therapy for PTSD represents a large opportunity as clinical trial data continues development following FDA advisory committee engagement and international regulatory review across multiple jurisdictions. Novel psychedelic drug development programs targeting non-hallucinogenic or short-duration analogs represent an emerging high-value opportunity as novel antidepressant mechanism analogs advance toward clinical validation.
5. Top Companies in the Psychedelic Market
The following organisations hold leading positions in the Psychedelic Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Compass Pathways plc
- ATAI Life Sciences
- Mind Medicine Inc. (MindMed)
- Numinus Wellness
- Journey Clinical
- Beckley Psytech
- CYBIN Inc.
- Bright Minds Biosciences
- GH Research
- FLJ Group
- Synthesis Institute
- Fluence Training
6. Market Segmentation
The Psychedelic Market is analysed across 7 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug Type | PsilocybinKetamineMDMALSD AnalogsDMT and Ayahuasca |
| By Therapy Type | Psychedelic-Assisted PsychotherapyKetamine Infusion TherapyPsychedelic Integration TherapyMicrodosing Programs |
| By Indication | Treatment-Resistant DepressionPTSD and TraumaAnxiety DisordersAddiction and Substance UseEnd-of-Life Anxiety |
| By Route of Administration | OralIntravenousIntranasalSublingual |
| By End User | Psychiatric ClinicsAddiction Treatment CentersResearch InstitutionsLicensed Therapy Centers |
| By Company Type | Clinical Stage DevelopersResearch OrganizationsKetamine Clinic OperatorsTherapy Training Providers |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Psychedelic Market trajectory over the forecast period:
Ketamine-Assisted Therapy Is the Commercially Established Anchor of the Legal Psychedelic Market.Esketamine nasal spray (Spravato) has established FDA-approved prescription revenue and ketamine infusion clinics provide off-label treatment for treatment-resistant depression outside the clinical trial setting. Janssen (J&J Pharmaceuticals) expanded Spravato prescribing access and insurance reimbursement coverage for treatment-resistant depression in 2024, growing the commercial market for regulated esketamine-assisted therapy.
Oregon Psilocybin Services Are Establishing the First Regulated Psychedelic Therapy Commercial Market.Licensed psilocybin service centers and facilitators operating under Oregon Measure 109 are creating the first commercial legal framework for non-ketamine psychedelic therapy outside clinical trials. Oregon psilocybin service center licensing expanded in 2024, with multiple facilities operating and therapist facilitator training programs certifying practitioners under the state's regulated psilocybin service framework.
Australia's TGA-Approved Psilocybin and MDMA Therapy Access Is Creating a Clinical Prescription Market.Australian Therapeutic Goods Administration authorization for psychiatrists to prescribe psilocybin and MDMA for treatment-resistant depression and PTSD created the first national prescription psychedelic drug market. Australian psychiatric clinics and Compass Pathways expanded MDMA and psilocybin therapy access under TGA authorization in 2024, with the program providing regulated access for qualifying patients outside the clinical trial setting.
For related market intelligence, see the Psilocybin Market.
8. Segmental Analysis
By drug type, the Ketamine segment dominated the Psychedelic Market in 2025, representing the largest revenue share as esketamine (Spravato) and off-label ketamine infusions constitute the commercially established and reimbursed psychedelic therapy market. The Psilocybin segment is the fastest-growing drug type category, advancing as regulated service access in Oregon, Colorado, Australia, and Europe creates legal commercial therapy channels beyond the clinical trial setting.
By indication, the Treatment-Resistant Depression segment dominated the Psychedelic Market in 2025, reflecting the large patient population lacking adequate response to conventional antidepressant treatment and the established clinical evidence base. The PTSD and Trauma segment is the fastest-growing indication category, driven by growing veteran and trauma survivor demand for MDMA-assisted therapy and expanding clinical access programs in authorized jurisdictions.
9. Regional Analysis
Regional demand patterns across the Psychedelic Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Psychedelic Market in 2025, holding 40.0% of the global market. Oregon's legal psilocybin service framework, Colorado's regulated psychedelic therapy access, and ketamine infusion clinic networks across the US represent the world's most developed legal psychedelic therapy infrastructure. Strong venture capital investment in US psychedelic drug development companies and the NIH's National Center for Complementary and Integrative Health funding for psychedelic research create an active development ecosystem. The high prevalence of treatment-resistant depression and PTSD in North American populations creates large unmet clinical need that drives patient and clinician demand for novel psychedelic-assisted treatment access.
Highest CAGR Region
Europe is expected to register the highest CAGR of 32.5% during the forecast period. Switzerland's legal psilocybin compassionate use program, the Netherlands' truffle-based psychedelic retreat infrastructure, and UK clinical research program expansion are creating legal psychedelic therapy access across Europe. Growing mental health treatment demand and regulatory engagement with psychedelic therapy in Germany, the UK, Spain, and Ireland are creating European clinical trial infrastructure that accelerates regulatory approval timelines. European academic research programs at universities in the UK, Netherlands, and Switzerland are generating peer-reviewed clinical evidence that increases physician awareness and regulatory acceptance of psychedelic therapeutic applications.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Psychedelic Market was valued at USD 3.72 Bn in 2025 and is projected to reach USD 12.60 Bn by 2034, growing at a CAGR of 14.50% over the 2026–2034 forecast period.
The Psychedelic Market is projected to grow at a CAGR of 14.50% from 2026 to 2034.
North America accounted for the largest share of the Psychedelic Market in 2025, holding 40.0% of the global market.
The leading companies in the Psychedelic Market include Compass Pathways plc, ATAI Life Sciences, Mind Medicine Inc. (MindMed), Numinus Wellness, Journey Clinical, Beckley Psytech, CYBIN Inc., Bright Minds Biosciences, GH Research, FLJ Group, Synthesis Institute, Fluence Training.
Ketamine-assisted therapy is the commercially established anchor of the legal psychedelic market.
By drug type, the Ketamine segment dominated the Psychedelic Market in 2025, representing the largest revenue share as esketamine (Spravato) and off-label ketamine infusions constitute the commercially established and reimbursed psychedelic therapy market.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.